Inspire Investing’s CytomX Therapeutics CTMX Stock Holding History

Inspire Investing’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17	Hold	6	–	–	﹤0.01%	1271
2026 Q2	$24	Hold	6	–	–	﹤0.01%	1253
2026 Q1	$30	Sell	6 -2	-25%	-$10	﹤0.01%	1086
2025 Q4	$32	Sell	8 -522,474	-100%	-$1.98M	﹤0.01%	1086
2025 Q3	$1.67M	Buy	+522,482	New	+$1.18M	0.16%	145
2020 Q2	–	Sell	-53	Closed	–	–	550
2020 Q1	$0	Buy	+53	New	+$370	﹤0.01%	753
2018 Q1	–	Sell	-58	Closed	-$1K	–	312
2017 Q4	$1K	Buy	+58	New	+$1.2K	﹤0.01%	853

Other funds holding CTMX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

Inspire Investing's CTMX Position: Q3 2026 in Review

Inspire Investing held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 6 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Inspire Investing first reported a position in CTMX in Q4 2017 and has held it in 7 quarters since. The position peaked at $1.67M in Q3 2025. 49 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

Inspire Investing held 6 shares of CytomX Therapeutics worth $17 as of Q3 2026.
Inspire Investing left its CytomX Therapeutics share count unchanged in Q3 2026.
CytomX Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q3 2026, its #1271 holding.
Inspire Investing first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 7 quarters since.
Inspire Investing's CytomX Therapeutics position peaked at $1.67M in Q3 2025.
49 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Inspire Investing's 13F filing for Q3 2026, filed 22 Oct 2026.